Ascendis Pharma A/S (ASND) was Initiated by Wedbush to “Outperform” and the brokerage firm has set the Price Target at $34. Wedbush advised their investors in a research report released on Sep 26, 2016.
Ascendis Pharma A/S opened for trading at $20.04 and hit $20.3 on the upside on Thursday, eventually ending the session at $19.97, with a gain of 0.81% or 0.16 points. The heightened volatility saw the trading volume jump to 41,951 shares. Company has a market cap of $502 M.
Ascendis Pharma A/S is a clinical stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its lead product candidate TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH the Company has developed a pipeline of long-acting prodrug product candidates such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH) TransCon Insulin for the treatment of diabetes TransCon Peptide for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology.